MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Positron emission tomography(PET)"

  • MDS Virtual Congress 2021

    Persistent and efficient transduction of the putamen following gene therapy for aromatic L-amino acid decarboxylase deficiency

    Y. Onuki, S. Ono, T. Nakajima, K. Kojima, N. Taga, K. Kawai, T. Sato, S. Muramatsu, T. Yamagata (Yakushiji, Japan)

    Objective: This study aimed to evaluate longitudinal transduction in subcortical regions and transduction of the cortico-putaminal network after putaminal AADC gene therapy. Background: Aromatic L-amino…
  • MDS Virtual Congress 2021

    Language impairment in Corticobasal Syndrome: from clinical phenotype to biomarkers

    J. Parmera, M. Oliveira, A. Coutinho, I. de Almeida, C. Carneiro, A. Neto, R. Nitrini, C. Buchpiguel, E. Barbosa, S. Brucki (São Paulo, Brazil)

    Objective: To investigate the language impairment profile of patients diagnosed as probable Corticobasal Syndrome (CBS) [1] in light of a multimodal imaging biomarkers analysis, namely…
  • MDS Virtual Congress 2020

    Impulse control disorder and ventral striatum dopamine D3 receptor availability in Parkinson’s disease

    G. Pagano, S. Molloy, P. Bain, E. Rabiner, K. Chaudhuri, D. Brooks, N. Pavese (Basel, Switzerland)

    Objective: To investigate the relationship between ventral striatum D3 dopamine receptor availability and severity of impulse control disorder (ICD) in Parkinson’s disease (PD). Background: Reduced…
  • MDS Virtual Congress 2020

    In vivo imaging of presynaptic terminal loss in early Parkinson’s disease

    A. Delva, D. Van Weehaeghe, M. Koole, K. Van Laere, W. Vandenberghe (Leuven, Belgium)

    Objective: To determine the magnitude and anatomical extent of presynaptic terminal damage in early Parkinson’s disease (PD) in vivo, we performed a PET study with…
  • MDS Virtual Congress 2020

    Levodopa-induced dyskinesias and substantia nigra dopamine D3 receptor availability in Parkinson’s disease

    G. Pagano, S. Molloy, P. Bain, E. Rabiner, K. Chaudhuri, D. Brooks, N. Pavese (Basel, Switzerland)

    Objective: To investigate with PET and the radioligand [11C]PHNO whether levodopa-induced dyskinesias in Parkinson disease (PD) are associated with dopamine-D3 receptor (D3R) overexpression in substantia nigra…
  • MDS Virtual Congress 2020

    Correlation between location of active contacts and weight gain after subthalamic nucleus deep brain stimulation in Parkinson’s disease

    K. Eguchi, I. Yabe, S. Shirai, M. Matsushima, T. Kano, K. Yamazaki, S. Hamauchi, T. Sasamori, K. Hirata, T. Seki, M. Kitagawa, M. Otsuki, T. Shiga, K. Hokin, H. Sasaki (Sapporo, Japan)

    Objective: Objective: The aim of this study was to evaluate the correlation between the location of active contacts and weight gain after subthalamic nucleus deep…
  • MDS Virtual Congress 2020

    Mechanisms of chronic neuroleptic-induced parkinsonism examined with positron emission tomography

    M. Galoppin, P. Berroir, J. Soucy, E. Stip, P. Blanchet (Montreal, QC, Canada)

    Objective: To investigate the cause of chronic neuroleptic drug-induced parkinsonism (NIP) through examination of the profile of striatal monoaminergic nerve terminal density using positron emission…
  • MDS Virtual Congress 2020

    Dopaminergic denervation in de-novo Parkinson’s disease. Does functional somatotopy plays a role?

    J.A Pineda-Pardo, A. Sánchez-Ferro, M. HM Monje, J.A Obeso (Móstoles, Spain)

    Objective: To clarify how dopaminergic denervation occurs along the dorsoventral axis of the posterior putamen in the earliest stages of PD. Background: Dopamine loss in…
  • MDS Virtual Congress 2020

    Topographical subtypes of multiple system atrophy: MRI and PET studies

    C. Lee, K. Park, N. Choi, S. Kim, J. Ko, D. Doudet (Seoul, Republic of Korea)

    Objective: To investigate the MSA subtypes based on the topography of MSA lesions, employing MRI, PET with [18F]FP-CIT and [18F]FDG PET. Background: Based on the…
  • MDS Virtual Congress 2020

    A longitudinal PET study to assess the state of microglia activation in a Phase 2 study of Laquinimod as a treatment for Huntington’s disease (LEGATO-HD)

    A.A Roussakis, M. Gennaro, M.F Gordon, R. Reilmann, B. Borowsky, G. Rynkowski, J.M Savola, M.R Hayden, R. Gunn, S. Tabrizi, P. Piccini (London, United Kingdom)

    Objective: To assess in vivo in Huntington’s disease (HD) changes in microglia activation state, due to treatment with laquinimod, as reflected by changes in 11C-PBR28…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 40
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley